Rybrevant 350 mg (Amivantamab SOLUTION) 350 MG

RYBREVANT 350 MG is an intravenous solution containing amivantamab, a targeted therapy used in cancer treatment. This medication is designed to help manage specific types of cancer by targeting certain proteins.

Strength

350 MG

Manufacturer / TM Owner

JANSSEN INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

RYBREVANT 350 MG is primarily used in the treatment of certain types of cancer. It works by targeting specific proteins that are involved in the growth and spread of cancer cells. This medication is often prescribed for patients who have not responded to other treatments. What is RYBREVANT used for? It is used for targeted cancer therapy, focusing on proteins that contribute to cancer cell proliferation.

Side Effects

Common effects of RYBREVANT 350 MG may include infusion-related reactions such as fever, chills, and fatigue. Some patients may also experience skin reactions or changes in blood pressure. These effects vary from person to person and are typically monitored by healthcare professionals.

Precautions & Warnings

RYBREVANT 350 MG should be handled with care and administered under the supervision of a healthcare professional. It is important to follow all safety guidelines provided by the manufacturer. Patients should be monitored for any adverse reactions during and after administration.

Avoid Interactions

RYBREVANT 350 MG may interact with other medications, including those that affect the immune system or blood pressure. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Always consult with a healthcare professional before starting any new treatment.

References

Frequently Asked Questions

RYBREVANT 350 MG is used in the treatment of certain types of cancer by targeting specific proteins involved in cancer cell growth.

RYBREVANT 350 MG is administered intravenously under the supervision of a healthcare professional.

Common side effects may include infusion-related reactions such as fever, chills, and fatigue, as well as skin reactions.

RYBREVANT 350 MG may interact with other medications, so it is important to consult with a healthcare professional before combining treatments.

Precautions include following all safety guidelines provided by the manufacturer and monitoring for adverse reactions during and after administration.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.